What this is
- How it works
- EGFR-targeted antibody-drug conjugate
- How it’s given
- “SYS6010 is Lyophilized powder for injection as an EGFR-ADC. SYS6010 will be administered via intravenous infusion, Q3W, with 21 days as one treatment cycle, at a dose of 4.5 mg/kg.”In the company’s words, NCT07633873 on ClinicalTrials.gov
- Tested for
- Non-Small Cell Lung Cancer (4 trials), Head and Neck Squamous Cell Carcinoma (2 trials), Esophageal Squamous Cell Carcinoma (2 trials), Advanced Solid Tumors (2 trials), EGFR-mutated Locally Advanced or Metastatic NSCLC, NSCLC, Locally Advanced/Metastatic/Recurrent ESCC, Recurrent or Metastatic Breast Cancer and 2 more
- Main trialPhase 3
- “To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)”In the company’s words, NCT06927986 on ClinicalTrials.gov
Coming up12
- 30 NovPhase 2 trial completes · ClinicalTrials.gov
- 12 DecPhase 3 trial completes · ClinicalTrials.gov
- 15 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Jun 2028Phase 2 trial completes · ClinicalTrials.gov
- 15 Sep 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 1 Apr 2029Phase 3 trial completes · ClinicalTrials.gov
- 30 Sep 2029Phase 3 trial completes · ClinicalTrials.gov
- 1 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes3
Last 90 days- 12 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07672223
- 9 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07924111
- 9 NovNew trial: none to Phase 3 · ClinicalTrials.gov NCT07925021
Trials15
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Jul 2026 | Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC(SYNSTAR01) | |
| Phase 3Not yet recruiting | 12 Dec 2026 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC | |
| Phase 3Not yet recruiting | 30 Sep 2027 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04) | |
| Phase 3Not yet recruiting | 30 Dec 2027 | SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ | |
| Phase 3Not yet recruiting | 15 Sep 2028 | SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCC | |
| Phase 3Not yet recruiting | 31 Dec 2028 | SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma | |
| Phase 3Not yet recruiting | 1 Apr 2029 | A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer | |
| Phase 3Recruiting | 30 Sep 2029 | A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC) | |
| Phase 3Recruiting | 1 Oct 2029 | A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma | |
| Phase 3Not yet recruiting | 30 Dec 2029 | A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection | |
| Phase 2/3Not yet recruiting | 30 Dec 2029 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | |
| Phase 2Not yet recruiting | 30 Nov 2026 | A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | |
| Phase 2Recruiting | 30 Jun 2028 | SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma | |
| Phase 1/2Not yet recruiting | 15 Jun 2027 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | |
| Phase 1/2Recruiting | 30 Oct 2027 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026